# US 10,870,854 B2 · Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,854 B2
- Document ID: US10870854B2
- Status: Granted
- Kind: B2
- Application number: 16/308,669
- Filed: 2017-05-24
- Published: 2019-05-23
- Granted: 2020-12-22
- Earliest claimed: 2016-06-09
- Assignees: Board of Regents, The University of Texas System
- Applicants: The Board of Regents of the University of Texas System
- Inventors: Hao Zhu; Shuyuan Zhang
- Web page: https://patentgrep.com/patent/US10870854B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/1077: {Beam delivery systems}
- A61P 35/00: Antineoplastic agents
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/351: Conjugate
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/31: Combination therapy
- C12N 2330/51: Specially adapted vectors
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the present disclosure include compositions and methods related to certain siRNA compositions for the treatment of cancer. In specific embodiments, siRNAs are employed for treatment of cancer, including at least liver cancer. Therapeutic methods, compositions, and kits are encompassed in the disclosure.

## Claims

### Claim 1

A method of treating a liver cancer in a subject comprising administering to the subject an effective amount of an interfering RNA or vector encoding the interfering RNA, where the interfering RNA targets an anillin actin binding protein mRNA.

### Claim 2 (depends on 1)

The method of claim 1, wherein the interfering RNA or vector is delivered by liposome or nanoparticle.

### Claim 3 (depends on 1)

The method of claim 1, wherein said interfering RNA or vector is administered systemically or regional to said liver cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein said interfering RNA or vector is administered intravenously, intratumorally, intrahepatically, intra-arterially, subcutaneously, topically or orally.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method further comprises administering an additional anti-cancer therapy to the individual.

### Claim 6 (depends on 5)

The method of claim 5, wherein the additional anti-cancer therapy comprises surgery, radiation, chemotherapy, hormone therapy, immunotherapy, or a combination thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the radiation comprises external beam radiation therapy.

### Claim 8 (depends on 1)

The method of claim 1, wherein said administering is repeated.

### Claim 9 (depends on 1)

The method of claim 1, wherein said liver cancer is recurrent or drug resistant.

### Claim 10 (depends on 1)

The method of claim 1, wherein said interfering RNA is about 21-23 bases in length.

### Claim 11 (depends on 1)

The method of claim 1, comprising a sequence at least 80%, 85%, 90% or 95% identical to SEQ ID NO: 1.

### Claim 12 (depends on 1)

The method of claim 1, comprising the sequence of SEQ ID NO: 1.

### Claim 13 (depends on 1)

The method of claim 1, consisting of the sequence of SEQ ID NO: 1.

### Claim 14 (depends on 1)

The method of claim 1, wherein the liver cancer is metastatic from a liver cancer or metastatic to the liver.